Print this page
Sunday, 06 December 2015 16:23

Anticoagulation news items. Weeks commencing 30th November 2015

Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis

The Lancet Haematology

Review of 71 studies found heart failure is a common independent risk factor for venous thromboembolism, with overall relative risk of 1.51 (1.36–1.68). Researchers suggest thromoboprophylaxis should be considered in clinical practice for high-risk patients.


Data on phase III ROCKET-AF trial of rivaroxaban to be reanalysed after discovery investigators used faulty point of care device (INRatio)

British Medical Journal

The device has been subject to recall following reports it could deliver INR results "clinically significantly lower" vs. laboratory INR method. This could have made rivaroxaban appear safer in terms of bleeding risk. European Medicines Agency has launched investigation.


What are the risks of using antiplatelet agents in combination with the Novel Oral Anticoagulants (NOACs) in patients with atrial fibrillation, and how should the potential risks be managed?


This new Medicines Q&A examines the risks of using antiplatelet medicines in combination with oral anticoagulants and how these risks may be managed.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: